• 提示：详情请下载说明书。

• 产品描述： Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.

• 靶点： INCB018424（180 mg/kg,口服,每天两次）显著减少JAK2V617F驱动的小鼠模型中脾肿大和炎性细胞因子的循环水平,并优先消灭肿瘤细胞,显著延长生存期,且未产生骨髓抑制或免疫抑制.上述小鼠在第22天存活率超过90％.15 mg Ruxolitinib处理骨髓纤维化患者,每天两次,在48周时,28％患者的脾脏体积减少至少35％.Ruxolitinib组的患者整体生活质量改善,与骨髓纤维化有关的症状减轻.;TyrosineKinases; JAK

• 细胞实验： Cell lines: Ba/F3 and HEL cells. Concentrations: 3 μM. Method: Cells are seeded at 2×103/well of white bottom 96-well plates,treated with INCB018424 from DMSO stocks (0.2% final DMSO concentration),and incubated for 48 hours at 37 ℃ in an atmosphere containing 5% CO2.Viability is measured by cellular ATP determination using the Cell-Titer Glo luciferase reagent or viable cell counting.Values are transformed to percent inhibition relative to vehicle control,and IC50 curves are fitted according to nonlinear regression analysis of the data using PRISM GraphPad.

• 动物实验： Animal Models: JAK2V617F-driven mouse modelFormulation & . Dosages: 5% dimethyl acetamide,0.5% methylcellulose.180 mg/kg. Administration: Oral gavage

• 参考文献：
  1. Harrison C, et al. N Engl J Med, 2012, 366(9), 787-798. 2. Verstovsek S, et al. N Engl J Med, 2012, 366(9), 799-807. 3. Quintas-Cardama A, et al. Blood, 2010, 115(15), 3109-3117.

• 溶解性： Soluble  in  DMSO、H2O、Ethanol

• 保存条件： -20℃

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	3.264 ml	16.32 ml	32.64 ml
  5 mM	0.653 ml	3.264 ml	6.528 ml
  10 mM	0.326 ml	1.632 ml	3.264 ml
  50 mM	0.065 ml	0.326 ml	0.653 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *